Blood Patents (Class 530/829)
-
Patent number: 5593968Abstract: A virus-inactivated Factor-Xa preparation with at least 100 units coagulation factor activity per mg protein is described, wherein this preparation is produced by activation of a corresponding starting material and subsequent treatment for the inactivation of infectious agents, particularly viruses. By incubation, the preparation obtained in this manner is transformed into a stable beta-Factor Xa preparation. In addition, the use of the present preparation for the treatment of hemophilia A inhibitor patients is disclosed.Type: GrantFiled: August 2, 1994Date of Patent: January 14, 1997Assignee: Immuno AktiengesellschaftInventors: Peter Turecek, Eibl Johann, Hans-Peter Schwarz
-
Patent number: 5591710Abstract: Compositions and processes to alleviate oxygen toxicity are disclosed based on the addition of nitroxides to physiologically compatible macromolecules. In particular, hemoglobin-based red cell substitutes are described featuring stable nitroxide free radicals for use in cell-free hemoglobin solutions, encapsulated hemoglobin solutions, stabilized hemoglobin solutions, polymerized hemoglobin solutions, conjugated hemoglobin solutions, nitroxide-labelled albumin, and nitroxide-labelled immunoglobulin. The formulations described herein interact with free radicals, act as antioxidant enzyme-mimics, and alleviate oxidative stress and oxygen-related toxicity.Type: GrantFiled: August 15, 1994Date of Patent: January 7, 1997Inventor: Jen-Chang Hsia
-
Patent number: 5589571Abstract: A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.Type: GrantFiled: October 28, 1994Date of Patent: December 31, 1996Assignee: COR Therapeutics, Inc.Inventor: Robert King
-
Patent number: 5589572Abstract: A process for producing a highly purified preparation of an inhibited form of an activated blood factor entails providing a partially purified preparation containing the blood factor of interest, treating the partially purified preparation to convert the blood factor to an inhibited activated form in a single step, and then purifying the resulting inhibited activated blood factor.Type: GrantFiled: June 7, 1995Date of Patent: December 31, 1996Assignee: COR Therapeutics, Inc.Inventor: Robert King
-
Patent number: 5589462Abstract: A method for the preparation of a platelet factor-enriched biological adhesive comprising freezing a platelet-enriched plasma and isolating a cryoprecipinate from the frozen platelet-enriched plasma is disclosed. Also disclosed is a method for biological adhesion employing the prepared biological adhesive.Type: GrantFiled: July 15, 1994Date of Patent: December 31, 1996Assignee: InotebInventors: Jean-Louis Patat, Olivier Delmas, Roland Schmitthaeusler
-
Patent number: 5585466Abstract: Serum albumin crystal forms have been produced which exhibit superior x-ray diffraction quality. The crystals are produced from both recombinant and wild-type human serum albumin, canine, and baboon serum albumin and allow the performance of drug-binding studies as well as genetic engineering studies. The crystals are grown from solutions of polyethylene glycol or ammonium sulphate within prescribed limits during growth times from one to several weeks and include the following space groups: P2.sub.1, C2, P1.Type: GrantFiled: December 6, 1994Date of Patent: December 17, 1996Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space AdministrationInventor: Daniel C. Carter
-
Patent number: 5583199Abstract: A 68 kDa a calmodulin-binding protein obtained from cytoplasmic or nuclear eukaryotic cell fractions, which is induced in hemopoietic factor-dependent cell lines by at least one of the following cytokines: granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin-3 or interleukin-6.Type: GrantFiled: November 19, 1993Date of Patent: December 10, 1996Assignee: University of Virginia Patents FoundationInventors: Peter J. Quesenberry, G. Prem-Veer Reddy
-
Patent number: 5576297Abstract: Opossum whole serum exhibits a life saving property by neutralizing the lethality of venoms from all major families of poisonous snakes, and therefore an injection of Opossum serum can used as a novel treatment for many types of envenomation. Preferably, the injectable treatment for envenomation should be a composition obtained from the fraction of Opossum whole serum which contains the lethal toxin neutralizing factor, i.e. the so called "natural LTNF", in purity. A method is given for the manufacture of a lethal toxin neutralizing factor from the serum of an opossum (Didelphis virginiana) serum, by fractionating the opossum serum and isolating this select fraction from the plurality of fractions having an N terminal amino acid sequence given by SEQ ID No: 1. A short peptide was synthesized having SEQ ID No: 1. The synthetic peptide having sequence SEQ ID No: 1 shows lethal toxin neutralizing activity similar to the natural LTNF from opossum or mongoose sera. The synthetic LTNF also has life saving utility.Type: GrantFiled: September 22, 1994Date of Patent: November 19, 1996Inventors: Binie V. Lipps, Frederick W. Lipps
-
Patent number: 5574139Abstract: The present invention relates to a method for the production of a powdered protein product from whole blood or a blood cell fraction separated from whole blood, the protein product being highly digestible, having a low content of iron and salts, being light brown, watersoluble and having good adhesive properties. The method for the production of the powdered protein product is characterized in that an aqueous blood cell material is subjected to hydrolysis at a temperature of between 140.degree. and 190.degree. C. and that the treated material is separated into a low-iron, liquid phase containing soluble proteins and an iron-rich, solid phase containing insoluble proteins, the liquid phase subsequently being concentrated or dried to a low-iron protein product, if desired.Type: GrantFiled: November 9, 1994Date of Patent: November 12, 1996Assignee: daka a.m.b.aInventor: Bjarne Holm-Jensen
-
Patent number: 5563041Abstract: The invention relates to a method for determining platelet aggregation in the presence of an inhibitor of fibrin aggregation, which prevents the formation of an interfering fibrin clot, and to a diagnostic aid for determining the platelet aggregation-inhibiting action of thrombin inhibitors.Type: GrantFiled: December 29, 1994Date of Patent: October 8, 1996Assignee: Behringwerke AktiengesellschaftInventor: Martin Reers
-
Patent number: 5561115Abstract: Highly stable plasma-derived therapeutic albumin solutions, having a turbidity level of 5 NTU or less can be made by adding sodium caprylate to Cohn fraction II+III or IV-1 effluent at relatively low temperatures. The sodium caprylate acts as a partitioning agent to separate albumin from unwanted proteins. In preferred embodiments, the albumin source solution temperature is elevated, increased in pH and reacted for approximately six hours under conditions sufficient to disrupt the initial solution colloid, and partition albumin-containing supernatant from a colloidal disperse phase, which retains unwanted globulins and manufacturing debris. Since it tends to be a scavenger molecule, albumin is selectively stabilized by diafiltration against a buffer containing sodium caprylate, thereby assuring a high albumin monomer content and low turbidity level. The amount of sodium caprylate required for selective stabilization is determined by the amount of available binding sites on the albumin molecule.Type: GrantFiled: August 10, 1994Date of Patent: October 1, 1996Assignee: Bayer CorporationInventor: Robert A. Tenold
-
Patent number: 5561114Abstract: This invention provides a selective cellular fibronectin (cFN) adsorbent utilizing a nonwoven cellulose sulfate fabric and a method for fractional purification of FN which comprises contacting an FN matter containing both plasma fibronectin (pFN) and cellular fibronectin (cFN) with the nonwoven cellulose sulfate fabric to separate pFN and cFN from each other. By the fractional purification method of the invention, cFN and pFN can be fractionated in an expedient manner and with high efficiency and both pFN and cFN can be recovered in high purity and good yield.Type: GrantFiled: May 25, 1994Date of Patent: October 1, 1996Assignees: Otsuka Pharmaceutical Factory Inc., Nissinbo Industries Inc.Inventors: Takashi Komai, Keiichi Miyashita, Eiji Sakashita, Hiroshi Kamogawa, Fujio Inoue, Soichiro Takenishi
-
Patent number: 5552381Abstract: Human membrane cofactor protein (MCP), a protein involved in regulation of complement activity, has been purified to homogeneity. The cDNAs encoding six isoforms of this protein have been retrieved and permit deduction of the complete amino acid sequences and the recombinant production of proteins with this activity. Pharmaceutical compositions in which MCP is the active ingredient for use in treating autoimmune diseases, antibody preparations for diagnosis, and DNA probes are also disclosed.Type: GrantFiled: February 28, 1994Date of Patent: September 3, 1996Assignee: Washington UniversityInventor: John P. Atkinson
-
Patent number: 5552529Abstract: A novel autoantigenic polypeptide, PINCH, polynucleotides and antibodies that bind to PINCH are provided. A method for removing autoantibodies that bind to an epitope contained in PINCH from a sample, such as blood, and a method of treating autoimmune disorders associated with autoantibodies that bind an epitope in PINCH are also provided.Type: GrantFiled: June 30, 1994Date of Patent: September 3, 1996Assignee: The Regents of the University of CaliforniaInventor: Ann Rearden
-
Patent number: 5548066Abstract: An immunological serum and method of making same. The serum essentially consists of purified and concentrated materials, sometimes known as transfer factor, and immunoglobulins, expressed from the clotted blood of a donor group having known immunity. To produce the serum, a group of donors is chosen which includes known immunity, preferably to a wide variety of ailments. Blood is drawn from the donor group and allowed to clot. Thereafter, the blood is filtered to remove all cellular material, producing raw serum. This raw serum is then concentrated by removal of water. The concentrated serum is then sterilized, but not denatured, by freezing and gamma irradiation.Type: GrantFiled: December 2, 1994Date of Patent: August 20, 1996Assignee: Central Biomedia, Inc.Inventors: Harry Leneau, William G. Skelly
-
Patent number: 5510464Abstract: This invention provides a method to therapeutically increase perfusion in a mammal comprising administering stroma-free hemoglobin at a dose ranging from the least amount effective to increase perfusion, up to a dose of about 2500 mg per kilogram of body weight.Type: GrantFiled: May 3, 1994Date of Patent: April 23, 1996Assignee: Baxter International Inc.Inventor: Robert J. Przybelski
-
Patent number: 5503827Abstract: The present invention concerns a process for the production of well-tolerated, preserved injection or infusion solutions containing human protein.Type: GrantFiled: February 15, 1994Date of Patent: April 2, 1996Assignee: Boehringer Mannheim GmbHInventors: Heinrich Woog, Werner Gruber, Hans-Jorg Markl, Gerhard Winter, Fritz Demmer
-
Patent number: 5480973Abstract: A proteinaceous product comprises a stable, substantially clear, thermally irreversible gel formed by the reaction product of protein and reducing sugar, preferably containing from 2 to 25% gel-forming protein by weight. Particles or pieces of edible material may be embedded in the gel, or the gel may be divided into pieces and incorporated as an ingredient in a food product, and the product can be rendered commercially sterile while remaining substantially clear. Such products can be produced by a process which comprises reacting an aqueous dispersion of a protein or proteinaceous material with a reducing sugar or source thereof in the presence of a denaturing agent (e.g. a chaotropic agent), and/or denaturing conditions (e.g. alkaline pH).Type: GrantFiled: October 21, 1993Date of Patent: January 2, 1996Assignee: Nadreph LimitedInventors: John S. Goodlad, Jonathan R. Cant, Stephen Harford
-
Patent number: 5476839Abstract: Several natural polypeptides (basophil granule proteins, "BGP") derived from the cytoplasmic granules of human basophils, and modified forms thereof, are described. These polypeptides, the DNA which encodes them and antibodies which recognize them, are useful as diagnostics for, and treatments for, pathologies involving inflammatory and IgE-mediated responses, parasitic and helminthic infections, hypersensitivity reactions and certain types of leukocytic leukemias.Type: GrantFiled: May 19, 1994Date of Patent: December 19, 1995Assignees: Incyte Pharmaceuticals, Inc., Mayo Foundation for Medical Education and ResearchInventors: Randy W. Scott, Gerald J. Gleich, Craig G. Wilde
-
Patent number: 5451664Abstract: An isolated and purified substance called Acta having the following features: (a) a molecular weight of 60 kd to 70 kd in SDS-PAGE using 12.5% gel, (b) reacts with a monoclonal antibody which is secreted by hybridoma FERM BP-3482, (c) binds to chymotrypsin and (d) binds to DNA. Acta is used to diagnose cancer and Alzheimer's disease.Type: GrantFiled: December 20, 1993Date of Patent: September 19, 1995Assignee: Konica CorporationInventors: Masahiko Yamasaki, Numa Masayuki
-
Patent number: 5439882Abstract: An improved blood substitute comprises purified hemoglobin, preferably bovine, cross-linked intramolecularly with periodate-oxidized ATP (o-ATP) and intermolecularly with periodate-oxidized adenosine (o-adenosine), combined with reduced glutathione (GSH), and optionally enriched with mannitol, non-electrolytes, and/or electrolytes. The blood substitute has prolonged intravascular persistence, can sustain plasma volume, has low oxygen affinity, can work as a physiological oxygen carrier, has vasodilator activity and can reduce the vasoconstriction that follows hemorrhage. A method of treating a human afflicted with acute blood loss and/or a sickling crisis of sickle cell anemia comprises intravenously administrating to the human an effective volume of the blood substitute.Type: GrantFiled: May 14, 1993Date of Patent: August 8, 1995Assignee: Texas Tech University Health Sciences CenterInventors: Mario Feola, Jan S. Simoni, Peter C. Canizaro, deceased
-
Patent number: 5432059Abstract: A method is provided for detecting carbohydrate-deficient glycoproteins in samples taken from subjects with metabolic disorders, such as alcohol abuse and subjects who display a syndrome of carrying abnormal levels of carbohydrate deficient glycoproteins. The method involves steps of reglycosylating with a fluorescent-conjugate deglycosylated glycoproteins in a sample of body fluid from a subject. A further step involves fluorometric detection of fluoresceinylated carbohydrates incorporated into truncated serum glycoproteins.Type: GrantFiled: April 1, 1994Date of Patent: July 11, 1995Assignee: Specialty Laboratories, Inc.Inventors: Pamela Bean, Jeff W. Terryberry
-
Patent number: 5346991Abstract: A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.Type: GrantFiled: June 13, 1991Date of Patent: September 13, 1994Assignee: Genentech, Inc.Inventors: Soumitra Roy, Gordon A. Vehar
-
Patent number: 5334706Abstract: This invention provides a method to therapeutically increase perfusion in a mammal comprising administering stroma-free hemoglobin at a dose ranging from the least amount effective to increase perfusion, up to a dose of about 2500 mg per kilogram of body weight.Type: GrantFiled: January 30, 1992Date of Patent: August 2, 1994Assignee: Baxter InternationalInventor: Robert J. Przybelski
-
Patent number: 5328990Abstract: Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.Type: GrantFiled: April 26, 1991Date of Patent: July 12, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Graeme J. Wistow
-
Patent number: 5317011Abstract: The present invention provides for the purification from native sources or the cloning and expression of a variant form of platelet factor 4 and also provides recombinant DNA vectors and methods for the expression and recovery of the platelet factor 4 variant. Also provided are compositions and methods for modulating immune responses in mammals comprising immunomodulating effective amounts of platelet factor 4 variant.Type: GrantFiled: November 9, 1992Date of Patent: May 31, 1994Assignee: SRI InternationalInventors: Christopher J. Green, Paul H. Johnson
-
Patent number: 5304383Abstract: There is disclosed a pharmaceutical preparation based on Lys-plasminogen and available in the lyophilized form. This preparation contains a serine-protease inhibitor and optionally an inhibitor co-factor, preferably in an amount of 0.5 to 30 nmol per mg Lys-plasminogen. This preparation is free of side-effects and may be used for the treatment and prophylaxis of plasminogen deficiency syndromes and thromboses as well as for the production of thromboresistant artificial organs.Type: GrantFiled: October 8, 1991Date of Patent: April 19, 1994Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Anton Philapitsch, Hans P. Schwarz
-
Patent number: 5250661Abstract: B cell differentiation factor which acts on B cells and participates in their differentiation into antibody-producing cells is produced by an established cell line.Type: GrantFiled: May 5, 1992Date of Patent: October 5, 1993Assignee: Mitsui Toatsu Chemicals IncorporatedInventors: Yoshiyuki Kanai, Akira Awaya
-
Patent number: 5250295Abstract: A factor (NKEF) for use in enhancing the activity of natural killer cells both in vivo and in vitro. NKEF is a soluble red blood cell cytosol protein having a molecular mass of between about 300 and 400 kilodaltons as determined by gel filtration high pressure liquid chromatography and an apparent molecular weight of about 48 kilodaltons as determined by non-reducing SDS-PAGE.Type: GrantFiled: November 4, 1991Date of Patent: October 5, 1993Assignee: The Regents of the Univ. of CaliforniaInventors: Hungyi Shau, Sidney H. Golub
-
Patent number: 5247069Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.Type: GrantFiled: June 2, 1992Date of Patent: September 21, 1993Assignee: OncogenInventors: Jeffrey A. Ledbetter, Edward A. Clark
-
Patent number: 5214033Abstract: Fragments of the factor VIII:C polypeptide have been discovered which exhibit highly specific factor VIII activity. Monoclonal antibodies to the polypeptide fragments and methods for the isolation and purification of said fragments are also disclosed.Type: GrantFiled: July 15, 1991Date of Patent: May 25, 1993Assignee: Scripps Clinic & Research FoundationInventors: Theodore S. Zimmerman, Carol A. Fulcher
-
Patent number: 5175255Abstract: Monoclonal antibodies specific for epitopes found on the B chain of PDGF (including v-sis, c-sis and platelet-derived forms) may be bound to columns and used for purification of rPDGF B. A solution containing a polypeptide possessing at least part of the structural conformation of rPDGF B is passed over such a column and the rPDGF B is bound to the antibody. The rPDGF B may then be eluted from the column to yield rPDGF B of greater than 95% purity as determined by SDS-PAGE.Type: GrantFiled: March 23, 1987Date of Patent: December 29, 1992Assignee: Amgen Inc.Inventors: Arlen R. Thomason, Margery A. Nicolson
-
Patent number: 5159063Abstract: A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.Type: GrantFiled: February 2, 1989Date of Patent: October 27, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Carl H. Hammer, Ruth M. Jacobs, Michael M. Frank
-
Patent number: 5149544Abstract: The invention comprises a factor having the following characteristics:a) It inhibits granulocyte-macrophage colony and cluster formation;b) It has a molecular weight of about 8 kDa as determined by SDS-PAGE;c) It has a weak anionic charge at pH 7.4 as shown by anion exchange chromatography;d) It has a flattened isoelectric titration curve as shown by anion exchange chromatography; ande) It is a protein.The invention also comprises methods of making and using the factor and compositions comprising the factor.Type: GrantFiled: November 13, 1989Date of Patent: September 22, 1992Assignee: Research Corporation Technologies, Inc.Inventors: Patrick S. Gentile, Charlie R. Mantel, Hal E. Broxmeyer
-
Patent number: 5110906Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.This invention also provides a method for treating a subject infected with a human immunodeficiency virus.Type: GrantFiled: February 24, 1988Date of Patent: May 5, 1992Assignees: The Trustees of Columbia University in the City of New York, Smithkline Beckman CorporationInventors: Paul J. Maddon, Richard Axel, Raymond W. Sweet, James Arthos
-
Patent number: 5104977Abstract: A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.Type: GrantFiled: February 8, 1989Date of Patent: April 14, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael B. Sporn, Anita B. Roberts, Richard K. Assoian, Charles A. Frolik
-
Patent number: 5101016Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.Type: GrantFiled: October 10, 1990Date of Patent: March 31, 1992Assignee: Scripps Clinic and Research FoundationInventors: Theodore S. Zimmerman, Carol A. Fulcher
-
Patent number: 5089274Abstract: The present invention provides a method of inhibiting lipopolysaccharide (LPS)-mediated stimulation of cells. This method comprises contacting the cells, in the presence of a cell-stimulating amount of lipopolysaccharide, with Bactericidal/Permeability Increasing Protein (BPI) in an amount effective to inhibit cell stimulation.Type: GrantFiled: January 22, 1990Date of Patent: February 18, 1992Assignee: INCYTE Pharmaceuticals, Inc.Inventors: Marian N. Marra, Randal W. Scott
-
Patent number: 5073487Abstract: A simple, rapid and reliable assay for measuring functional enzyme inhibitor levels in body fluids and tissues, especially functional .alpha..sub.1 -proteinase inhibitor levels in human plasma or serum. .alpha..sub.2 -Macroglobulin is first inactivated, then porcine pancreatic elastase incubated with the samples to form a complex between the elastase and the functional .alpha..sub.1 -PI. Deficient individuals are detected by the presence of a color change following addition of substrate. If desirable, residual enzyme activity can then be calculated and the .alpha..sub.1 -PI levels present in the original sample determined. The method provides a means for early screening of individuals with a genetic deficiency in circulating levels of .alpha..sub.1 -PI, thereby facilitating treatment and prevention of familial emphysema.Type: GrantFiled: January 30, 1989Date of Patent: December 17, 1991Assignee: Athens Research and Technology, Inc.Inventor: Cynthia A. Lloyd
-
Patent number: 5066787Abstract: This invention discloses proteins which inhibit the coagulation of the blood, processes for preparing these proteins, and the use thereof.Type: GrantFiled: November 23, 1987Date of Patent: November 19, 1991Assignee: Boehringer Ingelheim International GmbHInventor: Christian P. M. Reutelingsperger
-
Patent number: 5041370Abstract: The present invention provides a recombinant DNA sequence encoding the pseudorabies virus (PRV) glycoprotein gX, host cells transformed by said DNA sequence, the gX polypeptide, and methods and kits for detecting animals infected with PRV.Type: GrantFiled: April 17, 1986Date of Patent: August 20, 1991Assignee: The Upjohn CompanyInventors: deceased Hamdy, by Heide M Hamdy, heir, Roger J. Brideau, Leonard E. Post, Thomas J. Rea, James G. Timmins, Carmine C. Marchioli
-
Patent number: 5037958Abstract: A new immunosuppressive factor derived from human T cell leukemia cells characterized by the following properties:(1) molecular weight: 45,000 to 65,000 daltons and 150,000 to 200,000 daltons by gel filtration, and approximately 31,000 daltons by SDS-polyacrylamide gel electrophoresis;(2) isoelectric point: 4.6 to 4.8;(3) being elutable at a concentration of 0.31 to 0.32 M sodium chloride by FPLC-Mono Q anion exchange chromatography;(4) not adsorbable to immobilized concanavalin A Sepharose or blue Sepharose;(5) resistant to deoxyribonuclease, ribonuclease, papin and periodic acid but sensititive to trypsin, .alpha.-chymotrypsin or pronase;(6) stable at pH 2 to 10;(7) stable for a long time at 4.degree. C. but partially inactivated by heat treatment at 56.degree. C. or 90.degree. C. for 30 minutes;(8) not inhibitable by 2-mercaptoethanol, levamisole, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, .alpha.Type: GrantFiled: December 12, 1987Date of Patent: August 6, 1991Assignee: Yoshitomi Pharmaceutical Industries, Ltd.Inventors: Yoshiyuki Hashimoto, Kenji Chiba, Hirotsugu Komatsu, Takeki Okumoto
-
Patent number: 5026826Abstract: A purified inhibitor free human neutrophilic granulocyte end-stage maturation factor (GMF) inhibitor-free human neutrophilic granulocyte end-stage maturation factor is disclosed. The GMF is distinct from granulocyte colony stimulating factor (G-CSF) in both physical and biological properties.Type: GrantFiled: November 21, 1988Date of Patent: June 25, 1991Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Warren H. Evans, Shirley M. Wilson
-
Patent number: 5017556Abstract: A method and therapeutic composition for the treatment of bleeding disorders, for example those characterized by a tendency toward hemorrhage or a hypercoagulative state, by the administration of tissue factor protein or antagonists thereof.Type: GrantFiled: March 8, 1989Date of Patent: May 21, 1991Assignee: Genentech, Inc.Inventors: Donogh P. O'Brien, Gordon A. Vehar
-
Patent number: 5004802Abstract: A protein called PA binding protein has been isolated which binds specifically and reversibly to tissue plasminogen activator. The protein is characterized by a molecular mass of about 100,000 daltons, and electrophoretic mobility in agarose at pH 8.6 equal to that of plasma .beta.-globulins and an isoelectric point of 6.5 to 7.0. The protein is thermostable up to at least 56.degree. C. and is cleared from the circulation with a half life on the order of days.Type: GrantFiled: July 11, 1986Date of Patent: April 2, 1991Assignee: Nederlandse Centrale Organisatie voor Teegepast-Natturwentenschappelijk OrderzoelInventor: Cornelis Kluft
-
Patent number: 4959308Abstract: The present invention involves a method for producing a substrate useful in a system for the detection of antibodies directed against platelet antigens. This method comprises several steps. A platelet sample of interest is initially treated with an aqueous solution comprising a dialyzable nonionic detergent. This initial treatment is under conditions to solubilize platelet components and produce a platelet lysate. Such conditions may involve treatment of a platelet sample with an aqueous solution comprising nonionic detergent at a concentration between about 0.2% and about 0.5%. Platelet antigens are most preferably solubilized for about 30 min and at about 0.degree. C. in an aqueous solution comprising about 1 mg dialyzable nonionic detergent per mg platelet protein.The partially purified platelet antigens resulting from these manipulations are then preferably affixed to a solid matrix.Type: GrantFiled: August 27, 1987Date of Patent: September 25, 1990Assignee: Board of Regents, The University of Texas SystemInventor: Daryl M. Ogden
-
Patent number: 4957903Abstract: The invention relates to a fully solubilizable fibrin based composition, which is characterized by the combination that the fibrin is desAA-fibrin or desAA-fibrin from which the C-terminal portions of the .alpha.-chains have been removed by enzymatic digestion, and that the solubilizing agent is a tetrapeptide containing the amino acid sequence -L-prolyl-L-arginyl-, preferably glycyl-L-prolyl-L-arginyl-L-prolin.The full solubility of the fibrin makes possible new uses within the area of determination of important fibrinolytical parameters, and the invention also relates to three such important alternative uses. A first use according to the invention is the use of the composition in connection with detection or quantification of the activity of the enzyme tissue plasminogen activator.Type: GrantFiled: November 20, 1986Date of Patent: September 18, 1990Assignee: Biopool International, Inc.Inventor: Mats G. Ranby
-
Patent number: 4956278Abstract: Anaplasma marginale antigen, antigen compositions, vaccine and process for the production of said antigen, antigen composition and vaccine are disclosed. The Anaplasma marginale is free of the erythrocyte antigens that cause neonatal isoerythrolysis, and effective as a vaccinate which will not only protect the vaccinate against bovine anaplasmosis, but does not induce neonatal isoerythrolysis in offspring of vaccinates.Type: GrantFiled: February 23, 1988Date of Patent: September 11, 1990Assignee: Louisiana State UniversityInventors: Lewis T. Hart, Donald G. Luther, William J. Todd
-
Patent number: 4931548Abstract: A polypeptide transforming growth factor found in porcine platelets, having activity in the TGF-.beta. assay and a molecular weight of about 25 kDa. The factor is a heterodimer, one chain of which has an N-terminal sequence very different from human platelet TGF-.beta., and the other chain of which has an N-terminal sequence identical to that of human platelet TGF-.beta.. The factor is purified using gel filtration and reverse phase HPLC.Type: GrantFiled: January 30, 1987Date of Patent: June 5, 1990Assignee: Techne CorporationInventors: Roger C. Lucas, James A. Weatherbee, Monica L.-S. Tsang
-
Patent number: 4920097Abstract: Methods of extracting an immunosuppressor from leukocyte dialysates are disclosed, together with methods for using the immunosuppressor and compositions containing the immunosuppressor.Type: GrantFiled: October 12, 1988Date of Patent: April 24, 1990Assignee: Imreg, Inc.Inventors: A. Arthur Gottlieb, Robert C. Sizemore, Sudhir K. Sinha